In briefBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f436 (Published 22 January 2013) Cite this as: BMJ 2013;346:f436
Nicotinic acid with laropiprant is suspended in Europe: Doctors across Europe have been told to stop prescribing the combination of nicotinic acid with laropiprant (marketed as Tredaptive, Pelzont, or Trevaclyn) to treat dyslipidaemia, after a review by the European Medicines Agency. The move came after preliminary results from the HPS2-THRIVE (www.thrivestudy.org) study indicating that the combination taken together with a statin had no significant additional benefit over statin treatment alone in reducing the risk of major vascular events. The risk of non-fatal adverse events, including intracranial and gastrointestinal bleeding, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial